The Immunity By Design summit arrives as a pivotal meeting point for the world’s foremost scientists, clinicians, and biotech executives focused on the next generation of immune cell engineering. Set against the backdrop of Sweden’s burgeoning research landscape, the conference aims to dissolve traditional silos between academia, industry and healthcare, fostering a dynamic environment where groundbreaking ideas can cross-pollinate. Early-career researchers are explicitly invited to the dialogue, ensuring the next wave of innovators can contribute fresh perspectives to a field that is advancing at breakneck speed.
Organisers describe the event as a catalyst for “rethinking how to control immune responses,” a slogan that reflects the ambition to move beyond ex-vivo cell manipulation toward in vivo immune engineering. By embracing technologies that edit or program immune cells directly inside patients, the summit positions itself at the forefront of a transformation that could reshape therapeutic strategies for cancer, autoimmune disorders, and infectious diseases.
Conference vision: bridging ecosystems for translational impact
At its core, Immunity By Design strives to cement a durable research ecosystem that draws strength from both Swedish excellence and international expertise. The programme features a blend of keynote talks, panel discussions and interactive workshops that spotlight synthetic immunology advanced gene delivery technologies and the latest in immune cell therapy. Participants will hear about recent pre-clinical successes, such as engineered T-cells that recognize multiple tumor antigens, and clinical milestones where CRISPR-edited macrophages have shown promise in early trials. The overarching narrative emphasizes moving discoveries from the bench to the bedside as efficiently as possible.
Key thematic tracks and scientific breakthroughs
Three primary tracks structure the scientific agenda. The first track delves into immune engineering platforms exploring modular receptors, synthetic transcription factors, and programmable cytokine circuits. Speakers will present data on how these tools enable precise modulation of immune activity without the need for traditional drug dosing. The second track examines gene delivery vehicles ranging from viral vectors optimized for safety to non-viral nanoparticles engineered for tissue-specific uptake. Recent case studies highlighted include lipid-nanoparticle formulations that achieve robust transfection of splenic dendritic cells in mouse models. The final track focuses on translational pathways discussing regulatory considerations, manufacturing scale-up, and real-world patient monitoring strategies that accelerate the transition from prototype to approved therapy.
Collaboration hubs and early-career pathways
Beyond scientific sessions, the conference dedicates substantial time to networking hubs designed to spark collaborations. A “match-making lounge” pairs academic laboratories with biotech start-ups based on complementary expertise, while a series of mentorship circles give graduate students and post-docs direct access to senior leaders. Organisers also announced a grant-instigator program that will award seed funding to interdisciplinary projects conceived during the event, reinforcing the commitment to turning conversation into concrete research initiatives.
By congregating a diverse set of stakeholders—scientists shaping the toolbox, clinicians defining therapeutic endpoints, and industry players scaling production—the conference creates a fertile ground for the next generation of immune-based treatments. Attendees leave with a clearer view of how to harness the body’s own defenses, a network of collaborators ready to co-develop solutions, and a renewed sense that in vivo immune engineering will soon become a mainstream therapeutic reality.
